Immunotherapy is a groundbreaking cancer treatment offered by the experts at Moffitt Cancer Center. As pioneers of this promising option, we believe it has unprecedented potential to make a difference in the lives of many current and future cancer patients. By capitalizing on the natural power of the body’s immune system, novel immunotherapy treatments can help defend a patient’s body against the growth and spread of cancerous cells.
At Moffitt, patients can access numerous different immunotherapy treatments through our clinical trials program. As a National Cancer Institute-designed Comprehensive Cancer Center, we have a robust research program and are able to match patients with a variety of cancers with clinical trials that meet their unique needs. Physicians may refer their patients to Moffitt to access a variety of immunotherapy treatments, including:
- Cancer vaccines
- Monoclonal antibodies
- Immune checkpoint inhibitors
- Cellular immunotherapy, also called adoptive cell therapy, including:
- Chimeric antigen receptor (CAR) T-cell therapy
- Tumor-infiltrating lymphocyte (TIL) therapy
- T-cell receptor (TCR) therapy
We conduct immunotherapy trials for patients with a variety of solid and liquid tumors, including advanced-stage melanoma, sarcoma, brain cancer, lung cancer, multiple myeloma, lymphoma, ovarian and breast cancer. Immune-based therapies hold exceptional promise. Therefore many of our trials are open to patients who have already completed one or more other treatments without obtaining the desired outcomes. To ensure that each patient receives the treatment that is most likely to benefit his or her unique situation, we conduct a comprehensive series of evaluations prior to enrolling a patient in a trial.
The multispecialty team of experts at Moffitt is committed to providing outstanding clinical care for patients who are receiving immunotherapies. As part of this process, we continually review each patient’s response to treatment and revise his or her treatment plan as necessary. The leadership at Moffitt is also continually recruiting outstanding new faculty members to further develop our immunotherapy program.